{"component": "definition", "props": {"groups": [{"size": 33, "snippet_links": [{"key": "quantity-of", "type": "clause", "offset": [150, 161]}, {"key": "per-cent", "type": "definition", "offset": [234, 242]}, {"key": "dry-weight", "type": "definition", "offset": [251, 261]}, {"key": "in-the-case", "type": "clause", "offset": [298, 309]}, {"key": "similar-products", "type": "clause", "offset": [324, 340]}, {"key": "the-material", "type": "definition", "offset": [423, 435]}, {"key": "other-media", "type": "definition", "offset": [559, 570]}], "snippet": "means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid, a quantity of soluble lead compound exceeding, when calculated as lead monoxide, five per cent of the \u201cdry weight\u201d of the portion taken for analysis. In the case of paints and similar products and other mixtures containing oil or fat the \u201cdry weight\u201d means the dry weight of the material remaining after the substance has been thoroughly mixed and treated with suitable solvents to remove oil, fats, varnish or other media.", "samples": [{"hash": "95keJvPQ6jt", "uri": "https://meglc.gov.in/pdf/Draft%20Meghalaya%20Occupational%20Safety,%20Health%20and%20Working%20Condition%20Rules,%202024.pdf", "label": "meglc.gov.in", "score": 17.7691230774, "published": false}, {"hash": "hnTYPfrIi3E", "uri": "https://aioe.in/wp-content/uploads/2022/05/Chandigarh-Occupational-Safety-Rules2021-Draft.pdf", "label": "aioe.in", "score": 16.9461174011, "published": false}, {"hash": "bXwnHcjdWtk", "uri": "https://legalitysimplified.com/wp-content/uploads/2022/01/Occupational-safety-chandigarh.pdf", "label": "legalitysimplified.com", "score": 11.0150585175, "published": false}], "hash": "fe53e7a82818a7bd4670db3932e2b438", "id": 1}, {"size": 29, "snippet_links": [{"key": "five-percent", "type": "clause", "offset": [225, 237]}, {"key": "dry-weight", "type": "definition", "offset": [245, 255]}], "snippet": "means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.", "samples": [{"hash": "7Xvu1zE0UM7", "uri": "https://www.simpliance.in/files/labour_code_docs/88762344_the-punjab-occupational-safety-health-and-working-conditions-rules-2021.pdf", "label": "www.simpliance.in", "score": 10.691991806, "published": false}, {"hash": "4iu0OIwYQux", "uri": "https://www.jklabour.com/uploads/files/f944570d588c2761bbb3.pdf", "label": "www.jklabour.com", "score": 10.553730011, "published": false}, {"hash": "kszxmgXbJj6", "uri": "https://dcimanipur.gov.in/documents/ManipurFactoriesRules2019_Upload.pdf", "label": "dcimanipur.gov.in", "score": 10.4332647324, "published": false}], "hash": "f698bce13c26bfb703f822e780f7fc30", "id": 2}, {"size": 10, "snippet_links": [{"key": "product-candidate", "type": "definition", "offset": [11, 28]}, {"key": "stage-of-development", "type": "clause", "offset": [59, 79]}, {"key": "on-the-effective-date", "type": "clause", "offset": [115, 136]}, {"key": "at-any-time", "type": "clause", "offset": [150, 161]}, {"key": "in-development", "type": "definition", "offset": [183, 197]}, {"key": "for-development", "type": "clause", "offset": [269, 284]}], "snippet": "means that Product Candidate which is in the most advanced stage of development. VX-680 shall be the Lead Compound on the Effective Date. If there is at any time no Product Candidate in development, then the Lead Compound shall mean the next Product Candidate selected for development.", "samples": [{"hash": "6wlJ604XC2X", "uri": "/contracts/6wlJ604XC2X#lead-compound", "label": "Exclusive Research Collaboration, License and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 23.6830940247, "published": true}, {"hash": "kKte11NmiTM", "uri": "/contracts/kKte11NmiTM#lead-compound", "label": "Exclusive Research Collaboration, License and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 21.0, "published": true}, {"hash": "jLuM6apysp9", "uri": "/contracts/jLuM6apysp9#lead-compound", "label": "Exclusive Research Collaboration, License and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 21.0, "published": true}], "hash": "1f6e1e540f2a6addc6725a2eeee08f9b", "id": 3}, {"size": 8, "snippet_links": [{"key": "quantity-of", "type": "clause", "offset": [150, 161]}, {"key": "per-cent", "type": "definition", "offset": [234, 242]}, {"key": "dry-weight", "type": "definition", "offset": [250, 260]}, {"key": "method-of-treatment", "type": "clause", "offset": [300, 319]}], "snippet": "means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid, a quantity of soluble lead compound exceeding, when calculated as lead monoxide, five per cent of the dry weight of the portion taken for analysis. The method of treatment shall be as follows:", "samples": [{"hash": "2gBppf080X9", "uri": "https://www.ricago.com/assets/front/base/file/file_management/608.pdf", "label": "www.ricago.com", "score": 16.4504261017, "published": false}, {"hash": "8EYgOHr6fMy", "uri": "https://labour.sikkim.gov.in/Uploads/AllFiles/133.pdf", "label": "labour.sikkim.gov.in", "score": 12.1567420959, "published": false}, {"hash": "iHODhZ6Ip3P", "uri": "https://storage.hrylabour.gov.in/uploads/labour_laws/Y2021/Sep/W3/D17/1631879843.pdf", "label": "storage.hrylabour.gov.in", "score": 10.8548936844, "published": false}], "hash": "f2cb7494102b1bf8f60dcc656f3c5ffc", "id": 4}, {"size": 8, "snippet_links": [{"key": "library-compound", "type": "definition", "offset": [8, 24]}, {"key": "research-plan", "type": "definition", "offset": [123, 136]}, {"key": "research-committee", "type": "definition", "offset": [147, 165]}, {"key": "procedure-for", "type": "definition", "offset": [203, 216]}, {"key": "exhibit-b", "type": "definition", "offset": [261, 270]}, {"key": "it-is-understood-and-agreed-that", "type": "definition", "offset": [279, 311]}], "snippet": "means a Library Compound which meets the specific physical, chemical and/or catalytic properties established either in the Research Plan or by the Research Committee for identifying a Lead Compound. The procedure for identifying a Lead Compound is set forth on Exhibit B hereto. It is understood and agreed that any Library Compound that is transferred from Symyx to TDCC and subsequently commercialized by or under authority of TDCC or its Affiliates shall be deemed a Lead Compound.", "samples": [{"hash": "4nfSTuejOS", "uri": "/contracts/4nfSTuejOS#lead-compound", "label": "Collaborative Research and License Agreement (Accelrys, Inc.)", "score": 22.1991786957, "published": true}, {"hash": "6Cmci8nWpw5", "uri": "/contracts/6Cmci8nWpw5#lead-compound", "label": "Collaborative Research and License Agreement (Symyx Technologies Inc)", "score": 18.0, "published": true}, {"hash": "3a1B7sj7ZEN", "uri": "/contracts/3a1B7sj7ZEN#lead-compound", "label": "Collaborative Research and License Agreement (Symyx Technologies Inc)", "score": 18.0, "published": true}], "hash": "7ae826d5cac67277cb9b51e908358334", "id": 5}, {"size": 6, "snippet_links": [{"key": "programme-compound", "type": "definition", "offset": [10, 28]}, {"key": "the-criteria", "type": "clause", "offset": [45, 57]}, {"key": "set-out", "type": "definition", "offset": [58, 65]}, {"key": "milestone-1", "type": "clause", "offset": [69, 80]}, {"key": "schedule-3", "type": "definition", "offset": [84, 94]}, {"key": "in-the-field", "type": "clause", "offset": [103, 115]}], "snippet": "means any Programme Compound which satisfies the criteria set out in Milestone 1 in Schedule 3 for use in the Field;", "samples": [{"hash": "jLgejHPlKLW", "uri": "/contracts/jLgejHPlKLW#lead-compound", "label": "Agreement for the Provision of Funding", "score": 33.2227554321, "published": true}, {"hash": "jU5lKhX8RSM", "uri": "/contracts/jU5lKhX8RSM#lead-compound", "label": "Agreement for the Provision of Funding (PTC Therapeutics, Inc.)", "score": 32.3169059753, "published": true}, {"hash": "kgs2Hcpy1Ih", "uri": "/contracts/kgs2Hcpy1Ih#lead-compound", "label": "Agreement for the Provision of Funding (PTC Therapeutics, Inc.)", "score": 22.3702945709, "published": true}], "hash": "bbbf65294941f46b575ec12fbff138c9", "id": 6}, {"size": 6, "snippet_links": [{"key": "section-32", "type": "definition", "offset": [34, 45]}], "snippet": "will have the meaning assigned in Section 3.2.", "samples": [{"hash": "gtQP8S7shv2", "uri": "/contracts/gtQP8S7shv2#lead-compound", "label": "Service Agreement (Signal Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "YjIfgMjlsD", "uri": "/contracts/YjIfgMjlsD#lead-compound", "label": "Service Agreement (Signal Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "KGtpYU2Uwt", "uri": "/contracts/KGtpYU2Uwt#lead-compound", "label": "Service Agreement (Signal Pharmaceuticals Inc)", "score": 18.0, "published": true}], "hash": "0101b4d2a7ca4945b8a0f2f19241a6c0", "id": 7}, {"size": 5, "snippet_links": [{"key": "schering-compound", "type": "definition", "offset": [17, 34]}, {"key": "with-respect-to", "type": "clause", "offset": [35, 50]}, {"key": "agree-to", "type": "clause", "offset": [69, 77]}, {"key": "development-candidate", "type": "clause", "offset": [134, 155]}], "snippet": "means any Hit or Schering Compound with respect to which the Parties agree to initiate a program of medicinal chemistry to identify a Development Candidate based upon the structure of such Hit or Schering Compound.", "samples": [{"hash": "kuAPiXMERk0", "uri": "/contracts/kuAPiXMERk0#lead-compound", "label": "Collaboration and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "fkc9bftpxIp", "uri": "/contracts/fkc9bftpxIp#lead-compound", "label": "Collaboration and License Agreement (Ligand Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "NLxlZ5c7Pe", "uri": "/contracts/NLxlZ5c7Pe#lead-compound", "label": "Collaboration and License Agreement (Ligand Pharmaceuticals Inc)", "score": 21.0, "published": true}], "hash": "4bf17a015595804865bd342346776190", "id": 8}, {"size": 5, "snippet_links": [{"key": "research-compound", "type": "definition", "offset": [8, 25]}, {"key": "success-criteria", "type": "definition", "offset": [61, 77]}, {"key": "ready-to", "type": "clause", "offset": [81, 89]}, {"key": "development-of", "type": "clause", "offset": [125, 139]}, {"key": "clinical-supplies", "type": "clause", "offset": [140, 157]}, {"key": "section-33", "type": "definition", "offset": [170, 181]}, {"key": "during-the-research-term", "type": "clause", "offset": [182, 206]}, {"key": "tail-period", "type": "definition", "offset": [210, 221]}, {"key": "the-terms", "type": "definition", "offset": [223, 232]}, {"key": "development-compound", "type": "clause", "offset": [233, 253]}], "snippet": "means a Research Compound that has been demonstrated to meet Success Criteria as ready to begin regulated safety studies and development of clinical supplies pursuant to Section 3.3 during the Research Term or Tail Period. The terms Development Compound and Lead Compound may be used interchangeably.", "samples": [{"hash": "emeRKDrqikU", "uri": "/contracts/emeRKDrqikU#lead-compound", "label": "Focused Collaboration Agreement (Regeneron Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "3uu1Ht3AeOi", "uri": "https://investor.regeneron.com/static-files/52abae9f-6106-45d0-9aa1-6f38568879c3", "label": "investor.regeneron.com", "score": 9.965092659, "published": false}, {"hash": "bNv3NN3IRdM", "uri": "https://investor.regeneron.com/index.php/static-files/52abae9f-6106-45d0-9aa1-6f38568879c3", "label": "investor.regeneron.com", "score": 9.3312797546, "published": false}], "hash": "6ddf64ebecb8bff0af5db8ae393937b2", "id": 9}, {"size": 4, "snippet_links": [{"key": "organic-compound", "type": "definition", "offset": [9, 25]}, {"key": "in-vivo-studies", "type": "clause", "offset": [61, 76]}, {"key": "sufficient-activity", "type": "definition", "offset": [88, 107]}, {"key": "research-programs", "type": "definition", "offset": [162, 179]}, {"key": "additional-compounds", "type": "clause", "offset": [201, 221]}], "snippet": "means an organic compound identified in screening assays and in vivo studies that shows sufficient activity to be a standard of comparison in medicinal chemistry research programs intended to identify additional compounds having superior potency, selectivity, in vivo activity, or other superior drug-like qualities.", "samples": [{"hash": "jrlFAEYZdrj", "uri": "/contracts/jrlFAEYZdrj#lead-compound", "label": "Exclusive License Agreement (Reata Pharmaceuticals Inc)", "score": 33.1587944031, "published": true}, {"hash": "4auc0K4miCb", "uri": "/contracts/4auc0K4miCb#lead-compound", "label": "Exclusive License Agreement", "score": 31.3408622742, "published": true}, {"hash": "5H3C6vwvG3a", "uri": "/contracts/5H3C6vwvG3a#lead-compound", "label": "Exclusive License Agreement (Reata Pharmaceuticals Inc)", "score": 27.0068454742, "published": true}], "hash": "dd506d98748e00fb4ec257612419011c", "id": 10}], "next_curs": "CloSVGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjYLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIWbGVhZC1jb21wb3VuZCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 347, "snippet": "means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid, a quantity of soluble lead compound exceeding, when calculated as lead monoxide, five per cent of the \u201cdry weight\u201d of the portion taken for analysis. In the case of paints and similar products and other mixtures containing oil or fat the \u201cdry weight\u201d means the dry weight of the material remaining after the substance has been thoroughly mixed and treated with suitable solvents to remove oil, fats, varnish or other media.", "title": "Lead Compound", "id": "lead-compound", "examples": ["Hemispherian shall promptly and in any event within 30 Business Days after the Asset Transfer Closing Date, deliver or arrange to have delivered to the Company the chemical and biological embodiments of the <strong>Lead Compound</strong> and the Secondary Compound with all related information and documentation (including without limitation, the properties, specifications, quantities, yields, packaging information of the <strong>Lead Compound</strong>)."], "related": [["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["licensed-compound", "Licensed Compound", "Licensed Compound"], ["development-candidate", "Development Candidate", "Development Candidate"], ["product-candidate", "Product Candidate", "Product Candidate"], ["licensed-compounds", "Licensed Compounds", "Licensed Compounds"]], "related_snippets": [], "updated": "2026-03-11T05:19:41+00:00"}, "json": true, "cursor": ""}}